Literature DB >> 24416469

Breast Cancer Biomarkers: Utility in Clinical Practice.

Fanny Le Du1, Naoto T Ueno2, Ana M Gonzalez-Angulo3.   

Abstract

Breast cancer is a heterogeneous disease. For the past decades, new technical tools have been developed for biomarkers at the DNA, RNA and protein levels to better understand the biology of breast cancer. This progress is essential to classify the disease into clinically relevant subtypes, which may lead to new therapeutic opportunities. Novel biomarker development is paramount to deliver personalized cancer therapies. Further, tumor evolution, being natural or under treatment pressure, should be monitored and "liquid biopsies" by detecting circulating tumor cells or circulating free tumor DNA in blood samples will become an important option. This paper reviews the new generation of biomarkers and the current evidence to demonstrate their analytical validity, clinical validity and clinical utility.

Entities:  

Keywords:  Biomarkers; Breast cancer; Clinical utility; Prediction; Prognosis

Year:  2013        PMID： 24416469      PMCID： PMC3882751          DOI： 10.1007/s12609-013-0125-9

Source DB:  PubMed          Journal:  Curr Breast Cancer Rep        ISSN： 1943-4588


  90 in total

Review 1.  Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.

Authors:  D Hompes; T Ruers
Journal:  Eur J Surg Oncol       Date:  2011-07-20       Impact factor: 4.424

2.  Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

Authors:  H A Azim; S Michiels; F Zagouri; S Delaloge; M Filipits; M Namer; P Neven; W F Symmans; A Thompson; F André; S Loi; C Swanton
Journal:  Ann Oncol       Date:  2013-01-20       Impact factor: 32.976

3.  Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.

Authors:  Cristina Raimondi; Angela Gradilone; Giuseppe Naso; Bruno Vincenzi; Arianna Petracca; Chiara Nicolazzo; Antonella Palazzo; Rosa Saltarelli; Franco Spremberg; Enrico Cortesi; Paola Gazzaniga
Journal:  Breast Cancer Res Treat       Date:  2011-02-05       Impact factor: 4.872

4.  Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells.

Authors:  Michal Mego; Ugo De Giorgi; Shahenaah Dawood; Xuemei Wang; Vicente Valero; Eleni Andreopoulou; Beverly Handy; Naoto T Ueno; James M Reuben; Massimo Cristofanilli
Journal:  Int J Cancer       Date:  2010-11-28       Impact factor: 7.396

5.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

6.  Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

Authors:  C Liedtke; K Broglio; S Moulder; L Hsu; S-W Kau; W F Symmans; C Albarracin; F Meric-Bernstam; W Woodward; R L Theriault; L Kiesel; G N Hortobagyi; L Pusztai; A M Gonzalez-Angulo
Journal:  Ann Oncol       Date:  2009-07-12       Impact factor: 32.976

7.  The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.

Authors:  Marieke E Straver; Annuska M Glas; Juliane Hannemann; Jelle Wesseling; Marc J van de Vijver; Emiel J Th Rutgers; Marie-Jeanne T F D Vrancken Peeters; Harm van Tinteren; Laura J Van't Veer; Sjoerd Rodenhuis
Journal:  Breast Cancer Res Treat       Date:  2009-02-13       Impact factor: 4.872

8.  Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.

Authors:  John M S Bartlett; Kenneth J Bloom; Tammy Piper; Thomas J Lawton; Cornelis J H van de Velde; Douglas T Ross; Brian Z Ring; Robert S Seitz; Rodney A Beck; Annette Hasenburg; Dirk Kieback; Hein Putter; Christos Markopoulos; Luc Dirix; Caroline Seynaeve; Daniel Rea
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

Review 9.  Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.

Authors:  Scott D Ramsey; William E Barlow; Ana M Gonzalez-Angulo; Sean Tunis; Laurence Baker; John Crowley; Patricia Deverka; David Veenstra; Gabriel N Hortobagyi
Journal:  Contemp Clin Trials       Date:  2012-09-18       Impact factor: 2.226

10.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Authors:  Galatea Kallergi; Maria A Papadaki; Eleni Politaki; Dimitris Mavroudis; Vassilis Georgoulias; Sophia Agelaki
Journal:  Breast Cancer Res       Date:  2011-06-10       Impact factor: 6.466
View more
  3 in total

Review 1.  Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.

Authors:  Mersedeh Rohanizadegan
Journal:  Cancer Genet       Date:  2018-02-24

2.  Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.

Authors:  Roberta Maltoni; Valentina Casadio; Sara Ravaioli; Flavia Foca; Maria Maddalena Tumedei; Samanta Salvi; Filippo Martignano; Daniele Calistri; Andrea Rocca; Alessio Schirone; Dino Amadori; Sara Bravaccini
Journal:  Oncotarget       Date:  2017-03-07

3.  Profiling of Protein Adducts of Estrogen Quinones in 5-Year Survivors of Breast Cancer Without Recurrence.

Authors:  Che Lin; Ding-Ru Chen; Shou-Jen Kuo; Chi-Yen Feng; Dar-Ren Chen; Wei-Chung Hsieh; Po-Hsiung Lin
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.